14
Participants
Start Date
July 11, 2023
Primary Completion Date
August 19, 2025
Study Completion Date
May 12, 2026
GDX012
GDX012 suspension for IV infusion.
Chemotherapy Agents
Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
MD Anderson Cancer Center, Houston
University of Alabama at Birmingham (UAB) Hospital, Birmingham
City of Hope, Duarte
Stanford University, Palo Alto
Sarah Cannon/CBCI, Denver
Comprehensive Cancer Center of Northwestern University, Chicago
Dana-Farber Cancer Institute, Boston
Washington University, St Louis
Roswell Park Comprehensive Cancer Center, Buffalo
Thomas Jefferson University, New York
Cleveland Clinic, Cleveland
OHSU Knight Cancer Institute, Portland
Tri-Star BMT/Sarah Cannon Nashville, Nashville
Medical College of Wisconsin, Milwaukee
Lead Sponsor
Takeda
INDUSTRY